Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 5, 2005, Pages 466-470

  Polyzos, Aristides ^a   Syrigos, Konstantinos ^a   Stergiou, John ^b   Panopoulos, Christos ^c   Potamianou, Anna ^d   Vamvakas, Lambros ^e   Georgoulias, Vassilios ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c Immunology Laboratory   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cisplatin; Gastric carcinoma; Weekly docetaxel

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ONDANSETRON;

ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRITIS; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN TOXICITY; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 17644363684     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0912-0     Document Type: Article

References (26)

1. Ajani JA (1998) Current status of therapy for advanced gastric cancer. Oncology 12 [Suppl 6]:99-102
2. Preusser P, Achterrath W, Wilke H, et al (1988) Chemotherapy of gastric cancer. Cancer Treat Rev 15:257-277
3. Webb A, Cunningham D, Scarffe JH, et al (1997) Randomized trial comparing epirubicin cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15(1):261-267
4. Cascinu S, Ficarelli R, Safi MAA, et al (1997) A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 33:1699-1702
5. Murad AM, Petroianu A, Guimaraes RC, et al (1999) Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 22:580-586
6. Kim YH, Shin SW, Kim BS, et al (1999) Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy in the treatment of advanced gastric carcinoma. Cancer 85:295-301
7. Kollmannsberger C, Quietzsch D, Haang C, et al (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, FA and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458-462
8. Stathopoulos GR, Rigatos SK, Fountzilas G, et al (2002) Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep 9:89-92
9. Mavroudis D, Kakolyris S, Kouroussis, et al (1999) First line treatment of advanced gastric cancer with docetaxel monotherapy and granulocyte colony-stimulating factor (G-CSF) (abstract 977). Proc Am Soc Clin Oncol 18:254a
10. Vanhoefer U, Wilke H, Harstrick A, et al (1999) Phase II study of docetaxel as second line chemotherapy (CT) in metastatic gastric cancer (abstract 1163). Proc Am Soc Clin Oncol 18:303a
11. Graziano F, Catalano V, Baldelli AM, et al (2000) A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11:1263-1266
12. Ajani JA, Fodor M, van Cutsem E, et al (2000) Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC) (abstract 957). Proc Am Soc Clin Oncol 19:247a
13. Roth AD, Maibach R, Martinelli G, et al (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301-306
14. Ridwelski K, Gebauer T, Fahlke J, et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47-51
15. Constenla M, Lorenzo I, Carrete N, et al (1999) Docetaxel with weekly high-dose-5-FU and leucovorin: a new combination in advanced gastric cancer (abstract 1079). Proc Am Soc Clin Oncol 18:281a
16. André T, Louvet C, Ychou M, et al (1999) Docetaxel-epirubicin as second-line treatment for patients with advanced gastric cancer (abstract 1062). Proc Am Soc Clin Oncol 18:277a
17. Murad AM, Vinholes J, Skare N, et al (2002) A phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil (5-FU) and epirubicin (EPI) in previously untreated advanced gastric cancer: a novel and effective regimen (abstract 650). Proc Am Soc Clin Oncol 21:163a
18. Fennely D, Aghajanian C, Shapiro F, et al (1997) Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192
19. Hainswoth JD, Burris HA III, Erland JB, et al (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16(6):2164-2168
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
21. Seidman AD, Murphy B, Hudis C, et al (1997) Activity of Taxol by weekly 1-hour infusion in patients with metastatic breast cancer: a phase II and pharmacologic study (abstract). Proc Am Soc Clin Oncol 16:148A
22. Koizumi T, Tsunoda T, Fujimoto K, et al (2001) Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer. Lung Cancer 34(1):125-131
23. Schütte W, Nagel S, Lantenschläger C, et al (2002) Randomized phase II study of weekly versus three-weekly docetaxel as second line chemotherapy for advanced non-small cell lung cancer (abstract 1228). Proc Am Soc Clin Oncol 21:308a
24. Camps C, Massuti B, Jinenez AM, et al (2003) Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small cell lung cancer: a Spanish Lung Cancer Group (SLCG) phase III trial (abstract 2514). Proc Am Soc Clin Oncol 22:625
25. Gridelli C, Illiano A, Salvagui S, et al (2003) Effect on quality-of-life of weekly vs 3-weekly docetaxel in second-line treatment of advanced non-small-cell-lung cancer. The DISTAL randomized phase 3 study (abstract 2515). Am Soc Clin Oncol 22:625a
26. Ohe Y, Niho S, Kakinuma R, et al (2004) A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 15:45-50